The U.S. Food & Drug Administration (FDA) has granted approval for a novel and less invasive belimumab (Benlysta®) treatment for children with systemic lupus erythematosus (SLE) ages five years and ...

The 200-mg subcutaneous injection is for children 5 years and older. HealthDay News — The US Food and Drug Administration has approved a 200 mg subcutaneous route of administration of Benlysta ...

Several years of preliminary research results suggest chimeric antigen receptor (CAR) T-cell therapy could benefit pediatric patients with refractory systemic lupus erythematosus (SLE). When diagnosed ...

Reducing steroids in favor of more targeted therapies can minimize organ damage in pediatric systemic lupus erythematosus, according to data presented at EULAR 2024 Congress. “As a pediatric ...

In this retrospective analysis, responses persisted with hydroxychloroquine treatment. Results of a study suggest treatment using hydroxychloroquine (HCQ) for immune thrombocytopenia (ITP) related to ...

Seattle Children’s is the first FDA-authorized site to deliver an experimental CAR T-cell therapy to children with lupus, the system said March 11. About 20% of lupus patients have disease onset ...

The FDA has approved obinutuzumab for the treatment of adults with active lupus nephritis who are receiving standard therapy, ...

Investing.com -- The U.S. Food and Drug Administration (FDA) has approved Roche Holding AG’s (SIX:RO) Gazyva/Gazyvaro ...